跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

O1014

Sigma-Aldrich

Octreotide

≥98% (HPLC)

登录查看公司和协议定价
所有图片(1)
别名:
SMS 201-995
经验公式（希尔记法）:
C49H66N10O10S2
CAS号:
83150-76-9
分子量:
1019.24
MDL编号:
MFCD00871400
UNSPSC代码:
12352200
PubChem化学物质编号:
329818892
NACRES:
NA.32

质量水平

200

检测方案

≥98% (HPLC)

溶解性

H2O: soluble

储存温度

−20°C

SMILES字符串

C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1

InChI

1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1

InChI key

DEQANNDTNATYII-OULOTJBUSA-N

基因信息

human ... SSTR1(6751) , SSTR2(6752) , SSTR3(6753) , SSTR4(6754) , SSTR5(6755)

正在寻找类似产品? 访问 产品对比指南

相关类别

Amino Acid Sequence

Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr-ol [Disulfide bridge: 2-7]

一般描述

Octreotide is a somatostatin analogue with D-Phe-Cys-Phe-D-Trp-Lys-ThrCys-Thr-OH amino acid sequence.

生化/生理作用

Octreotide is three times more potent than the native hormone in inhibiting the secretion of growth hormone glucagon and insulin in vivo. Octreotide regulates serum prolactin levels and resolves galactorrhea or (secondary) amenorrhea in acromegaly patients. Hence, this peptide can be considered as a potent therapeutic for acromegaly treatment.
Somatostatin analog that is 3-times more potent than the native hormone in inhibiting the secretion of growth hormone.

其他说明

Lyophilized from 0.1% TFA in H2O

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jan Calissendorff et al.
Endocrine, 47(1), 169-176 (2013-11-26)
Metastases from ileal neuroendocrine tumors (NETs) to the myocardium are rare and generally seen in patients with widespread metastatic NET disease. The objectives of this investigation were to describe the frequency of intracardiac metastases in ileal NET patients examined by
Octreotide as primary therapy for acromegaly.
Newman CB
The Journal of Clinical Endocrinology and Metabolism, 83(9), 3034-3040 (1998)
Alain Sauvanet et al.
Annals of surgery, 260(2), 364-371 (2014-03-22)
To assess the feasibility and outcomes of parenchyma-sparing pancreatectomy (PSP), including enucleation (EN), resection of uncinate process (RUP), and central pancreatectomy (CP), as an alternative to standard pancreatectomy for presumed noninvasive intraductal papillary and mucinous neoplasms (IPMNs). Pancreaticoduodenectomy and distal
Mattias Sandström et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(10), 1755-1759 (2013-08-10)
(68)Ga-DOTATOC and (68)Ga-DOTATATE are 2 radiolabeled somatostatin analogs for in vivo diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure their comparative biodistribution and radiation dosimetry. Ten patients diagnosed with neuroendocrine tumors were included.
Hendrik Bergsma et al.
Best practice & research. Clinical gastroenterology, 26(6), 867-881 (2013-04-16)
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门